Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Its analysis suggests that tezepelumab is similar to Dupixent in improving symptom scores and reducing the annualised asthma exacerbation rate (AAER) in eosinophilic asthma. It matched Xolair on ...

Additionally, these values were of a similar magnitude to those seen with dupilumab (Dupixent; Regeneron, Sanofi) vs. placebo, he said. “Both tezepelumab acting upstream and dupilumab acting ...

Initiations increased from 8% to 38% for dupilumab (Dupixent; Sanofi, Regeneron) and from less than 0.5% to 29% for tezepelumab (Tezspire; Amgen, AstraZeneca). Between the second halves of 2022 ...

This expansion positions Dupixent as the first targeted therapy ... AMGN/AstraZeneca’s tezepelumab, and GSK’s mepolizumab are in development, promising more options to transform COPD management.

SAN DIEGO -- Tezepelumab (Tezspire ... Monoclonal antibodies dupilumab (Dupixent), omalizumab (Xolair), and mepolizumab (Nucala) are already approved for treating chronic rhinosinusitis with ...

Tezepelumab (Tezspire) has shown significant clinical benefits in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), including marked reductions in nasal congestion and polyp ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.